CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 240 enrolled
Drug / intervention
Ropiniroledrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00357097
NCT00357097Phase 3Completed
CompareCT.gov

A Multicenter 3:1-randomized Placebo-controlled Double-blind Phase IIIb Study on the Effects of Ropinirole on Mood/(Subclinical) Depression in the Therapy of Patients With Moderate to Severe Idiopathic RLS in Germany

GlaxoSmithKline·interventional·Posted Jul 27, 2006·Updated Jun 7, 2012

In Brief

A Phase 3 clinical trial evaluating Ropinirole for Restless Legs Syndrome and Moderate to Severe Idiopathic Restless Legs Syndrome (RLS). Completed, enrolled 240 participants across 50 sites.

Detailed Summary

Ropinirole has shown to improve mood in depressed patients as well as to improve the symptoms of Restless Legs Syndrome. Up to 40% of RLS patients suffer from mild depression, therefore it would be important for decisions no therapy to know whether a drug could improve both depressive and RLS symptoms.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRestless Legs Syndrome, Moderate to Severe Idiopathic Restless Legs Syndrome (RLS)
CountriesGermany
Collaborators--

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 27, 2006
Enrollment StartJun 1, 2006
Primary CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 19.9 years ago

Interventions

Ropiniroledrug